Simulations Plus Releases ADMET Predictor® Version 12
July 30 2024 - 8:30AM
Business Wire
Enhancements in key models power HT-PBPK
simulations and AI-driven drug design with unprecedented
performance and accuracy
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a
leading provider of biosimulation, simulation-enabled performance
and intelligence solutions, and medical communications to the
biopharma industry, today announced the release of version 12.0 of
ADMET Predictor® (AP12), its flagship machine learning (ML)
modeling platform for the discovery, design, and optimization of
new molecules.
AP12 includes:
- Enhanced Models: New and expanded models offer greater
predictive accuracy, with an average 30% increase in training set
sizes, for microsome and hepatocyte clearance, protein binding,
biorelevant solubilities, MDCK-LE/PAMPA permeability, and
more.
- High-Throughput Pharmacokinetics (HTPK): New options for
solution dosing, adjusted free fraction outputs, and
species-specific simulations enhance the flexibility and precision
of HTPK studies.
- Artificial Intelligence-Driven Drug Design (AIDD):
Integration of 3D shape matching and tissue sensitivities (based on
tissue Kp values) as new objectives, facilitating innovative lead
optimization processes.
- New DILI Module: Introduction of the first drug-induced
liver injury (DILI) endpoint models to support high-throughput (HT)
DILIsym® predictions in early drug development.
- Boosted ANN Regression Models and added 37 new
descriptors in ADMET Modeler™.
- General Usability and Informatics Improvements.
Dr. David Miller, Vice President of Cheminformatics, said:
“ADMET Predictor 12 features substantial advancements in the
critical components required to build high-quality machine learning
models. This upgraded version integrates new premium data, novel
descriptors, and robust algorithms that will increase our
customers’ ability to predict with confidence. These enhancements
reinforce our commitment to providing state-of-the-art tools for
the scientific community.”
“Based on feedback from our customers, we are improving the
accuracy of essential models as well as extending the software’s
capabilities for integration and automation within existing
workflows,” added Dr. Eric Jamois, Director of Key Accounts and
Strategic Alliances. “The advances embedded in AP12 deliver
downstream benefits in HTPK, AIDD, and now, HT-DILI. We are
constantly innovating to take drug discovery research to the next
level and are very excited to introduce this new version to our
growing user community.”
Learn more about ADMET Predictor or request a demo.
About Simulations Plus, Inc.
With more than 25 years of experience serving clients globally,
Simulations Plus stands as a premier provider in the biopharma
sector, offering advanced software and consulting services that
enhance drug discovery, development, research, clinical trial
operations, regulatory submissions, and commercialization. Our
comprehensive biosimulation solutions integrate artificial
intelligence/machine learning (AI/ML), physiologically based
pharmacokinetics (PBPK), quantitative systems
pharmacology/toxicology (QSP/QST), and population PK/PD modeling
approaches. We also deliver simulation-enabled performance and
intelligence solutions alongside medical communications support for
clinical and commercial drug development. Our cutting-edge
technology is licensed and utilized by leading pharmaceutical,
biotechnology, and regulatory agencies worldwide. For more
information, visit our website at www.simulations-plus.com. Follow
us on LinkedIn | X | YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts
where we can have the most positive impact. To learn more about our
latest initiatives and priorities, please visit our website to read
our 2023 ESG update.
Forward-Looking Statements
Except for historical information, the matters discussed in this
press release are forward-looking statements that involve risks and
uncertainties. Words like “believe,” “expect” and “anticipate” mean
that these are our best estimates as of this writing, but there can
be no assurances that expected or anticipated results or events
will actually take place, so our actual future results could differ
significantly from those statements. Factors that could cause or
contribute to such differences include, but are not limited to: our
ability to successfully integrate the recently acquired
Pro-ficiency business with our own, as well as expenses we may
incur in connection therewith, to maintain our competitive
advantages, acceptance of new software and improved versions of our
existing software, the general economics of the pharmaceutical
industry, market conditions, macroeconomic factors, and a
sustainable market. Further information on our risk factors is
contained in our quarterly and annual reports and filed with the
U.S. Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240730491945/en/
Simulations Plus Investor Relations
Renee Bouche 661-723-7723 renee.bouche@simulations-plus.com
Financial Profiles Lisa Fortuna
310-622-8251 slp@finprofiles.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Jul 2023 to Jul 2024